Authors
Latest:
Justin Dubin, MD, on leveraging digital tools to improve patient buy-inJustin Dubin, MD, discussed how patients' growing trust in digital tools could be leveraged to support lifestyle changes and improve health outcomes.
Latest:
EP. 4B: The Effect of Leuprolide Formulations on Organizational Management Practices in Metastatic Prostate CancerIn this companion article, Brenda Heath, RN, discusses key challenges related to the use of leuprolide acetate and leuprolide mesylate from an organizational management perspective.
Latest:
Quiz: Testicular trauma in 21-year-oldA 21-year-old male presented to the emergency department for evaluation of testicular pain and swelling 5 days after being struck in the groin.
Latest:
Expert emphasizes significance of physician self-careIf you’re a doctor, your job is to take care of others. But too often, that comes at the expense of taking care of yourself.
Latest:
Future Horizons in PSMA-Targeted Imaging and the Management of Prostate CancerExperts close their discussion by highlighting the future landscape of PSMA-targeted imaging in the management of prostate cancer.
Latest:
Key Takeaways on Evolving Bladder Cancer Treatment LandscapeThe expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.
Latest:
Follow-Up After Negative Bone/CT in Prostate Cancer With Molecular RecurrenceDr Raoul Concepcion leads a multidisciplinary expert panel in a discussion about the challenges of long-term follow-up of prostate cancer in patients with negative bone/CT but positive molecular indicators of recurrence.
Latest:
A urologist on why the time is right to let go"It is the right time and I have been fortunate to have such great people to work with locally and nationally," a urologist writes.
Latest:
Jens Bedke, MD, on efficacy of EV plus pembrolizumab across subgroups in la/mUCEV+P demonstrated superior efficacy to chemotherapy across all specified subgroups assessed.
Latest:
Lisa F. Newcomb, PhD, on active surveillance for prostate cancer"My hope is that the results of our study improve the uptake of active surveillance, further reducing unnecessary treatments, and this, combined with the improving reflex tests, may change the risk-benefit of PSA screening," says Lisa F. Newcomb, PhD.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Michael Schweizer, MD, shares data on mevrometostat plus enzalutamide in mCRPC“We found that the median rPFS with the combo of mevrometostat plus enzalutamide was 14.3 months, which compared favorably with what we saw with the enzalutamide arm, where the median was only 6.2 months,” says Michael Schweizer, MD.
Latest:
Experts consider efficacy of fertility restoration vs sperm cryopreservation“While I would hesitate to say that reversal is truly better in terms of efficacy, I think this data suggests that it's at least as good,” says Scott D. Lundy, MD, PhD, HCLD.
Latest:
Extended lymphadenectomy yields no additional benefit vs standard procedure for urothelial cancerExtended lymph node dissection during radical cystectomy offered no additional overall survival or disease-free survival benefit vs standard lymph node dissection.
Latest:
Conservative management feasible for uncomplicated renal colic patients with positive urine cultures“Though septic stones are well recognized as a medical emergency, patients with uncomplicated renal colic (without systemic inflammatory responses or renal impairment) and positive urine cultures pose a dilemma in management considerations,” the investigators explained in their abstract.
Latest:
Case review: An incidentally discovered renal massAn expert panel discusses the case of a 65-year-old Caucasian male who is noted to have an incidental 3-cm right renal mass, enhancing on a contrasted CT scan as part of a routine follow-up for his metastatic castration-resistant prostate cancer, diagnosed in 2017 and currently undergoing therapy.
Latest:
2-year data show continued enfortumab vedotin efficacy in cisplatin-ineligible MIBCUpdated findings from cohort H of the EV-103 study showed promising 2-year event-free survival outcomes and favorable antitumor activity with enfortumab vedotin in cisplatin-ineligible patients with muscle-invasive bladder cancer.
Latest:
Optimizing SNM: PEER trials investigate potential of SNM lead sensingColin M. Goudelocke, MD, discusses the PEER trials, which are assessing the safety and efficacy of SNM lead sensing for optimizing SNM programming.
Latest:
Olaparib plus abiraterone/prednisone linked with improved PFS in mCRPCThe median PFS was 39 months (95% CI, 22-not reached [NR]) in arm 3 compared with 8.4 months (95% CI, 2.9-17.0) in arm 1 and 14 months (95% CI, 8.4-20.0) in arm 2.
Latest:
Apalutamide combo hits high 2-year RFS rate in prostate cancerTreatment with apalutamide and androgen deprivation therapy led to a 2-year biochemical recurrence-free survival rate of 100% in patients with high-risk, post-prostatectomy prostate cancer.
Latest:
Biomarkers in advanced prostate cancer: Liquid biopsy, ctDNA, and more"The management of advanced prostate cancer has evolved significantly, driven in part by the integration of diverse biomarkers that guide treatment decisions from diagnosis through progression," says Nedim Ruhotina, MD.
Latest:
Managing Cognitive and Sexual Health in Prostate Cancer Patients on Hormonal TherapyPanelists discuss how managing cognitive and sexual health in prostate cancer patients undergoing hormonal therapy is crucial, emphasizing the need for proactive communication and tailored interventions to enhance overall quality of life.
Latest:
AHN Offering Advanced Urological Care Close to Home for Patients in ErieThe recent expansion of AHN Saint Vincent Allied Urology was purposefully designed to enhance every aspect of the patient experience.
Latest:
Eric Jonasch, MD, on phase 1/2 trial of 177Lu-girentuximab combination in ccRCC“We really want to understand whether by using this beta emitter, together with the combination of cabazantinib and the nivolumab, we're getting better outcomes than we would expect with the doublet alone,” says Eric Jonasch, MD.
Latest:
Key Challenges in the Administration of Leuprolide for Advanced/Metastatic Prostate CancerIn the second article of the series, Paul Sieber, MD, shares best practices for the administration of leuprolide in patients with advanced/metastatic prostate cancer.
Latest:
The urologist in the world of precision medicine"What exactly is precision medicine?...One of the original [LUGPA] board members put it very simply: cheaper, faster, and better," writes Raoul S. Concepcion, MD, FACS.
Latest:
The status and future direction of advanced urine testing: multiplex PCR"Given that PCR testing may have a benefit for specific cohorts, it is recommended that more clinical evidence be provided to better guide Medicare in defining 'medical necessity,' ” write Stephanie Gleicher, MD, MPH, and Roger R. Dmochowski MD, MMHC, FACS.
Latest:
EP. 15: Subsequent Treatment Considerations for Patients with Unsatisfactory Responses to Third-Line Therapy for OABExperts close their panel on OAB by identifying treatment pathways for patients who have an unsatisfactory response to third-line therapy.
Latest:
Dr. Cheryl Iglesia highlights the evolving treatment paradigm for overactive bladder“New data indicate that long-term use of some of these overactive bladder drugs is not good for cognitive function,” explains Iglesia.
Latest:
Genomic and imaging advances drive precision medicine progress in prostate cancerRohan Garje, MD, discusses precision medicine in metastatic prostate cancer, including genomic testing, targeted therapies, and theragnostics.
